Securities code: 688185 securities abbreviation: Cansino Biologics Inc(688185) Announcement No.: 2022-012
Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company
Voluntary disclosure of recombinant New Coronavirus vaccine (type 5 adenovirus vector)
Announcement of approval for sequential booster immunization
The board of directors and all directors of the company guarantee that there are no false records, misleading statements or major omissions in the contents of this announcement, and bear legal responsibility for the authenticity, accuracy and integrity of its contents according to law.
1、 Overview
The joint prevention and control mechanism of the State Council held a press conference on February 19, 2022, at which it was announced that with the approval of the joint prevention and control mechanism of the State Council, the National Health Commission has begun to deploy the sequential enhanced immunization of covid-19 vaccine. Previously, target people over 18 years old who have been vaccinated with inactivated vaccine of Sinopharm Zhongsheng Beijing company, Beijing Kexing company, Sinopharm Zhongsheng Wuhan company or adenovirus vector vaccine of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) company (hereinafter referred to as “the company”) for 6 months can receive one dose of primary homologous booster immunization, that is, strengthen with the original vaccine. After the implementation of the sequential booster immunization strategy, the target population who has completed the whole process of vaccination with the above three inactivated vaccines can also choose the recombinant protein vaccine of zhifeilong Kema or the adenovirus vector vaccine of the company for sequential booster immunization. For the target population, one of homologous booster immunization and sequential booster immunization can be selected. Whether homologous enhancement or sequential enhancement, it should be implemented in people over 18 years old who have completed the whole process of vaccination for 6 months.
2、 Impact on the company
So far, the company’s recombinant New Coronavirus vaccine (type 5 adenovirus vector) (trade name: Ke Wei Sha) (hereinafter referred to as “the product”) has been granted China’s conditional approval and emergency use authorization in many other countries.
After the product is approved for sequential immunization, if the relevant national departments increase their procurement, it will have a certain positive impact on the performance of listed companies.
3、 Risk tips
1、 The conditional listing application of the product is in accordance with “Article 63 during the clinical trial of drugs, drugs that meet the following conditions can apply for conditional approval: (III) Vaccines urgently needed in response to major public health emergencies or other vaccines deemed urgently needed by the National Health Commission, the benefits outweigh the risks after assessment. “
2. After inquiry, up to now, four covid-19 vaccine products in China have been conditionally approved for listing, three have been approved for emergency use, and many others are in clinical trials. Even if the product is approved for sequential immunization, its future market sales will still face fierce competition, and will be affected by the development and changes of the epidemic situation outside China, covid-19 vaccination rate in China and other factors.
3. Please make careful decisions and pay attention to preventing investment risks. The information about the company shall be subject to the announcements published in China Securities News, securities times, Securities Daily, Shanghai Securities News and the website of Shanghai Stock Exchange.
It is hereby announced.
Board of directors of Cansino Biologics Inc(688185) Jinyu Bio-Technology Co.Ltd(600201) February 21, 2022
